MedTrace Logo

The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease

NCT06853743 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-03-19

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease. It will also learn about the safety of nicotinamide riboside. The main questions it aims to answer are:

* Does NR slow progression of overall symptom burden in Huntington's disease?
* Does NR have an effect on any specific symptom domain in Huntington's disease?
* Does supplementation with NR cause side-effects or safety issues when used for 2 years in Huntington's disease?
* Does NR have an effect on selected blood, imaging, and oculomotor biomarkers in Huntington's disease?

Researchers will compare NR to a placebo (a look-alike substance that contains no active compound) to see if NR works to treat Huntington's disease.

Participants will:

* Take 2000mg NR or a placebo every day for 2 years
* Visit the clinic once every 6 months for clinical investigations and tests
* Undergo brain imaging at baseline and upon completion of the study period

Conditions

  • Huntington Disease

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside (NR)

Nicotinamide riboside, 2 capsules of 500mg taken twice daily for 2 years

DIETARY_SUPPLEMENT

Placebo

Placebo, 2 capsules twice daily for 2 years

Sponsors & Collaborators

  • Haukeland University Hospital

    collaborator OTHER

  • South-Eastern Norway Regional Health Authority

    collaborator OTHER

  • Klinbeforsk

    collaborator OTHER

  • The Dam Foundation

    collaborator OTHER

  • Elysium Health

    collaborator INDUSTRY

  • NKS Olaviken Gerontopsychiatric Hospital

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Lasse Pihlstrøm, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06853743 on ClinicalTrials.gov